WO2022131350A1 - Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 - Google Patents
Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 Download PDFInfo
- Publication number
- WO2022131350A1 WO2022131350A1 PCT/JP2021/046645 JP2021046645W WO2022131350A1 WO 2022131350 A1 WO2022131350 A1 WO 2022131350A1 JP 2021046645 W JP2021046645 W JP 2021046645W WO 2022131350 A1 WO2022131350 A1 WO 2022131350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- dna
- substituted
- deoxyribonucleoside
- derivative
- Prior art date
Links
- 239000005549 deoxyribonucleoside Substances 0.000 title claims description 19
- 239000005547 deoxyribonucleotide Substances 0.000 title claims description 12
- 125000002637 deoxyribonucleotide group Chemical group 0.000 title claims description 12
- 108091023037 Aptamer Proteins 0.000 title abstract description 32
- 238000012216 screening Methods 0.000 title description 32
- 102000039446 nucleic acids Human genes 0.000 title description 13
- 108020004707 nucleic acids Proteins 0.000 title description 13
- 150000007523 nucleic acids Chemical class 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 37
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
- 238000009739 binding Methods 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 40
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 17
- 239000001226 triphosphate Substances 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 230000036961 partial effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- DIRINUVNYFAWQF-UHFFFAOYSA-N 4-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1[N+]([O-])=O DIRINUVNYFAWQF-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical class BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229940127554 medical product Drugs 0.000 claims description 4
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 238000010189 synthetic method Methods 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims description 2
- 239000000273 veterinary drug Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 108091008102 DNA aptamers Proteins 0.000 abstract description 38
- 239000002777 nucleoside Substances 0.000 abstract description 30
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 26
- 230000003993 interaction Effects 0.000 abstract description 15
- 239000002773 nucleotide Substances 0.000 abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 abstract description 9
- 238000012986 modification Methods 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- -1 nucleoside triphosphate Chemical class 0.000 description 69
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 64
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 50
- 238000003786 synthesis reaction Methods 0.000 description 50
- 102000053602 DNA Human genes 0.000 description 42
- 239000000203 mixture Substances 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 37
- 108020004682 Single-Stranded DNA Proteins 0.000 description 35
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 34
- 230000002829 reductive effect Effects 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 102000058223 human VEGFA Human genes 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229920002401 polyacrylamide Polymers 0.000 description 12
- 239000012300 argon atmosphere Substances 0.000 description 11
- 230000008034 disappearance Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 229910000175 cerite Inorganic materials 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229930192474 thiophene Natural products 0.000 description 6
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 238000009413 insulation Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- QSSJZLPUHJDYKF-UHFFFAOYSA-N methyl 4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1 QSSJZLPUHJDYKF-UHFFFAOYSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- UNWJSSMTMUUCGQ-UHFFFAOYSA-N 2-benzyl-5-bromothiophene Chemical compound S1C(Br)=CC=C1CC1=CC=CC=C1 UNWJSSMTMUUCGQ-UHFFFAOYSA-N 0.000 description 3
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 3
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000002715 modification method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- JDAHCKJCJRUNRQ-UHFFFAOYSA-N 2-[5-(cyclopentylidenemethyl)thiophen-2-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C2=CC=C(C=C3CCCC3)S2)OC1(C)C JDAHCKJCJRUNRQ-UHFFFAOYSA-N 0.000 description 2
- MSIDUAVZUIYMNK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[5-(naphthalen-2-ylmethyl)thiophen-2-yl]-1,3,2-dioxaborolane Chemical compound CC1(C)OB(C2=CC=C(CC3=CC4=CC=CC=C4C=C3)S2)OC1(C)C MSIDUAVZUIYMNK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 1
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 1
- MHCDPUQZSITUCR-UHFFFAOYSA-N 2-(cyclopentylmethyl)thiophene Chemical compound C=1C=CSC=1CC1CCCC1 MHCDPUQZSITUCR-UHFFFAOYSA-N 0.000 description 1
- BVOITXUNGDUXRW-UHFFFAOYSA-N 2-chloro-1,3,2-benzodioxaphosphinin-4-one Chemical compound C1=CC=C2OP(Cl)OC(=O)C2=C1 BVOITXUNGDUXRW-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 5-bromothiophene-3-carbaldehyde Chemical compound BrC1=CC(C=O)=CS1 ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WAYGVZKRYOMXQC-UHFFFAOYSA-N C(CC1)CC1C(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.Br Chemical compound C(CC1)CC1C(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.Br WAYGVZKRYOMXQC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000012391 XPhos Pd G2 Chemical group 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical group [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- WZYWSVSFFTZZPE-UHFFFAOYSA-M cyclopentyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C1CCCC1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WZYWSVSFFTZZPE-UHFFFAOYSA-M 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000006245 phosphate protecting group Chemical group 0.000 description 1
- WRMXOVHLRUVREB-UHFFFAOYSA-N phosphono phosphate;tributylazanium Chemical compound OP(O)(=O)OP([O-])([O-])=O.CCCC[NH+](CCCC)CCCC.CCCC[NH+](CCCC)CCCC WRMXOVHLRUVREB-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a deoxyribonucleoside or a deoxyribonucleotide having a novel artificial base that can be used for screening a DNA aptamer, and a nucleic acid containing the deoxyribonucleoside.
- a DNA aptamer is a single-stranded DNA having a chain length of 30 to 70 bases, which forms a specific thermodynamically stable three-dimensional structure by self-annealing to form a target molecule such as a low molecular weight compound or a protein. It is a general term for DNA molecular species that have become able to interact specifically. Since DNA aptamers have excellent affinity for target molecules and selectivity for interaction with target molecules, they are also called synthetic antibodies and are expected as a modality for next-generation drug discovery.
- Patent Document 1 the Systematic Evolution of Ligands by EXPONENTIAL ENRICHMENT (SELEX) method expired in 2011, research on aptamers has become active year by year, but the aptamer has been launched as a drug. So far, there is only one McGen® product. The reason for this is thought to be largely due to the pharmacokinetic properties of the DNA aptamer, but in addition to that, it is difficult to obtain an aptamer that binds to the target molecule due to the physical characteristics of the DNA aptamer, in other words. It is also considered that the physical characteristics of the DNA aptamer limit the variety of target molecules from which the aptamer can be obtained.
- the following factors can be considered as factors that limit the diversity of target molecules from which DNA aptamers can be obtained.
- the nucleobase which is a constituent unit, is widely used only in the four natural types (A, T, G, C). Therefore, compared to the existence of 20 kinds of natural amino acids, the natural nucleobase has a small number of structural units for forming an interaction, and accordingly, the types of combinations in which an interaction is formed are also scarce.
- the base portions of the four natural nucleobases are used to directly interact with target molecules such as proteins, but the structure of the natural base portions is poorly flexible and fat.
- oligonucleic acid containing DNA has a negative charge at the phosphate-binding moiety. For this reason, oligonucleic acid is difficult to interact with a negatively charged target molecule because it causes electrostatic repulsion, and there is a limit to the types of molecules that can be targeted by aptamers.
- Somalogic, Inc. of the United States uses a method (Post modification method) in which an artificial base having a flexible lipophilic substituent introduced is chemically synthesized after obtaining a seed aptamer by the SELEX method. I tried to solve it.
- Somalogic has succeeded in obtaining aptamers targeting more than 1000 proteins (Larry Gold, et al., PLos ONE, 2010, 5 (Larry Gold, et al., PLos ONE, 2010, 5). 11): e15004; Gupta S, et al., J. Biol. Chem. (2014) p8706-19).
- DNA aptamers obtained by the SELEX method often have a phosphate-binding moiety that interacts with a positively charged partial structure of the target molecule, and thus have a positively charged substituent.
- Introducing a base into an aptamer by Post modification causes electrostatic repulsion and may have an adverse effect. Therefore, in order for the DNA aptamer to acquire sufficient interaction with the negatively charged target molecule, a positively charged substituent is not introduced after the selection by modifying the base moiety.
- DNA aptamers can be obtained inexpensively in a short period of time because there is no need for post modification.
- the variety of target proteins for which DNA aptamers can be obtained has not been expanded. The reason is that although Ds is more lipophilic than natural bases, it is structurally less flexible and has sufficient interaction with target molecules to overcome the effects of charge and bind. It is possible that it has not been completed.
- the present invention has been made in view of such circumstances, and the problems of DNA aptamer acquisition in the above-mentioned conventional method, that is, lack of diversification of interaction with the target molecule, and aptamer acquisition cost by Post modification. It is an object of the present invention to overcome problems such as increase in aptamer and limitation of target molecular species due to electric charge, and to provide a technique for obtaining a highly active aptamer at the lowest possible cost.
- a novel artificial base that can be used for screening the DNA aptamer of the present invention and a nucleic acid containing the novel have the following constitutions.
- the first aspect of the present invention is a deoxyribonucleoside or deoxyribonucleotide having the structure of the following formula I as a base.
- R 1 is a substituted C 1 -C 3 alkyl group, a substituted or unsubstituted C 4 -C 9 alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or no substituted group.
- Substituted araalkyl group, substituted or unsubstituted heteroaryl group is a substituted C 1 -C 3 alkyl group, a substituted or unsubstituted C 4 -C 9 alkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or no substituted group.
- R 1 may be a phenyl group, a 4-pyridyl group, a naphthyl group, an isopropyl group, or a cyclopentyl group.
- it may be a deoxyribonucleotide having triphosphate at the 5'-hydroxyl group.
- it may be a deoxyribonucleoside having a protecting group at the 5'-hydroxyl group and a phosphoramidite group or an H-phosphonate group at the 3'-hydroxyl group.
- the second aspect of the present invention is a reagent for oligonucleic acid synthesis containing the deoxyribonucleoside or deoxyribonucleotide of the first aspect.
- a third aspect of the present invention is a pharmaceutical product containing the nucleoside or nucleotide of the first aspect.
- a fourth aspect of the present invention is a coupling reaction between a 2-bromothiophene derivative and a 2-amino-3-nitro-4-chloropyridine or 7-chloro-3H-imidazole [4,5-b] pyridine derivative.
- the method for synthesizing deoxyribonucleoside according to the first aspect which comprises the step of performing the above-mentioned step.
- the coupling reaction is carried out under Suzuki coupling reaction conditions.
- a fifth aspect of the present invention is an oligodeoxyribonucleic acid incorporating a deoxyribonucleoside having the base of the first aspect.
- the oligodeoxyribonucleic acid may be a DNA aptamer.
- a sixth aspect of the present invention is an oligonucleic acid or a derivative thereof, which comprises the oligodeoxyribonucleic acid of the fifth aspect as a partial structure.
- the seventh aspect of the present invention is a modified product in which an independent arbitrary molecular species is bound to the oligodeoxyribonucleic acid of the fifth aspect, or the oligonucleic acid of the sixth aspect or a derivative thereof.
- An eighth aspect of the present invention is a human or veterinary drug containing the oligodeoxyribonucleic acid of the fifth aspect, the oligonucleic acid of the sixth aspect or a derivative thereof, or the modified product of the seventh aspect. It is a raw material of the pharmaceutical product, an additive of a health food, or a diagnostic reagent.
- a ninth aspect of the present invention comprises disease treatment, lifesaving, and symptoms comprising the oligodeoxyribonucleic acid of the fifth aspect, the oligonucleic acid of the sixth aspect or a derivative thereof, or the modified product of the seventh aspect. It is a pharmaceutical product for the purpose of maintenance or maintenance of general condition.
- the pharmaceutical product may be a medical material, a medical material, a medical device or a medical product.
- a tenth aspect of the present invention is used for affinity column chromatography containing the oligodeoxyribonucleic acid of the fifth aspect, the oligonucleic acid of the sixth aspect or a derivative thereof, or the modified product of the seventh aspect.
- the nucleoside having an artificial base according to the present invention can be used for general purposes by synthesizing it by a synthetic method including a step of performing a coupling reaction between a 2-bromothiophene derivative and 2-amino-3-nitro-4-chloropyridine.
- the coupling reaction can be carried out without using the tin-containing intermediate.
- waste containing tin is not discharged, so that a synthetic method with a reduced environmental load can be obtained.
- deoxyribonucleoside having an artificial base according to the present invention By introducing deoxyribonucleoside having an artificial base according to the present invention into a DNA aptamer in advance, the ability of the interaction between the DNA aptamer and the target molecule can be improved by the functional group of the artificial base portion.
- the DNA in which deoxyribonucleoside having an artificial base of the present invention is incorporated can be PCRed with high fidelity, the functional group having an artificial base can be introduced from the selection stage, and post-modification is necessary. There is no. This reduces the number of steps for acquiring DNA aptamers and enables acquisition at a lower cost.
- nucleoside having an artificial base containing a heterocycle having a functional group having a positive charge under physiological conditions into a single-stranded DNA library for SELEX, a portion having a negative charge, which has been considered difficult in the past, is obtained. It also allows interaction with the structure.
- the oligodeoxyribonucleoside incorporating a deoxyribonucleoside having a base according to the present invention can be more flexible and enable appropriate interaction with a wider range of target proteins.
- the present inventors provide an artificial base that can be used by the SELEX method, that is, PCR can be performed with a high fidelity of the incorporated DNA, and can interact more flexibly with the target molecule.
- PCR can be performed with a high fidelity of the incorporated DNA, and can interact more flexibly with the target molecule.
- Ds (7- (2-thienyl) -3H-imidazole [4,5-b] -pyridine-3. -Il) was modified by introducing a lipophilic substituent or a substituent having a cationic partial structure, thereby completing the invention according to the present embodiment.
- the following effects are expected by introducing a fat-soluble substituent. -Improved affinity by forming a more effective hydrophobic interaction with the target molecule. -Promotion of complex formation with target molecules in water by improving the lipophilicity of the entire molecule and reducing its water solubility.
- the artificial bases according to this embodiment can be synthesized by a method including a step of performing a coupling reaction with 2-amino-3-nitro-4-chloropyridine.
- the coupling reaction can be carried out without using a commonly used tin-containing intermediate.
- waste containing tin is not discharged, so that the synthetic method can be made with a smaller environmental load than the conventional method using a tin-containing intermediate.
- scaled-up synthesis can be enabled.
- artificial base refers to an artificially formed nucleobase analog having properties similar to the base portion of a naturally occurring nucleoside.
- the artificial base according to the present embodiment has a complementary artificial base that selectively and specifically forms a base pair.
- Artificial base pairs are not limited to hydrogen bonds used for base pair formation between natural bases, but also physical bonds based on the structure or shape of artificial bases and stacking interactions such as ⁇ - ⁇ interactions. , Electrostatic bonds can be formed by sites with positive and negative charges.
- Ds refers to 7- (2-thienyl) -3H-imidazole [4,5-b] -pyridin-3-yl, which is one of the artificial bases.
- nucleoside refers to a compound in which a base moiety and a sugar are bound by a glycosidic bond.
- nucleotide refers to a compound in which a 5'-or 3'-hydroxyl group of a nucleoside is bonded to phosphoric acid to form a phosphoric acid ester.
- the "fat-soluble substituent” represents a substituent composed of only carbon, hydrogen, and halogen atoms.
- the "cationic substituent” is a substituent composed of a nitrogen atom, and a substitution in which a nitrogen atom is protonated to form a positive charge in the pH range of 4 to 8 to form a cation. Represents a group.
- the "derivative of an artificial base” means a base analog in which a part of the artificial base is substituted with the above-mentioned lipophilic substituent, cationic substituent, or other functional group.
- the nucleoside having an artificial base of this embodiment can also be used as a pharmaceutical product.
- the modulator of the adenosine receptor (Dilip K Tosh, et al., J. Med. Chem., 2012 (55), 4847-4860). ) Can be used.
- nucleoside phosphoromidite having an artificial base and nucleoside triphosphate The 3'-phosphoroamideite in which the 5'-hydroxyl acid of the nucleoside having an artificial base of the present embodiment is protected with an appropriate protecting group is under the same conditions as the natural base. It can be used for chemical synthesis of DNA as a component of DNA or oligonucleic acid by the solid phase synthesis method. Specifically, a general-purpose DNA chemical synthesizer in which a 5'-hydroxyl protection-3'-phosphoroamidite of a nucleoside having an artificial base according to the present embodiment is combined with a natural or modified nucleoside phosphoramidite. Can synthesize DNA having a desired chain length.
- the phosphoramidite moiety may be a commonly used 2-cyanoethyl-N, N'-diisopropylphosphoroamidite, where the 2-cyanoethyl group is another phosphate protecting group, N, N'-diisopropylphosphoroamidite. It may be another suitable amino group. Further, it may be a cyclic amidite in which NO is bonded.
- the 5'-triphosphate of the nucleoside having the artificial base of this embodiment can be synthesized by a general-purpose chemical synthesis method.
- nucleic acid containing a nucleoside having an artificial base The nucleotide having an artificial base of this embodiment functions in PCR because it can form a base pair with the complementary artificial base Px. That is, by adding the 5'-triphosphoric acid of the nucleoside having the artificial base of the present embodiment and the 5'-triphosphate of the nucleoside having Px to the PCR solution, the artificial base and Px of the present embodiment can be obtained. Double-stranded DNA with base pairs is amplified by PCR. Therefore, it can be used for screening aptamers by the SELEX method, which requires PCR.
- the number of artificial bases introduced during DNA synthesis by amplification by PCR is appropriately 1 to 5 in one DNA, preferably 3 or less.
- the artificial bases contained in one DNA may be the same, and the artificial bases forming different base pairs may be included. good. Further, a base pair may be formed in the same single chain to form a secondary structure or a tertiary structure.
- “Aptamer” generally refers to a medium-sized (10 to 100 bases) oligonucleic acid or peptide that binds to a specific molecule, or a derivative or modified product thereof. Oligonucleic acids or DNAs that include the artificial base of this embodiment and bind to a particular molecule fall into the category of DNA aptamers.
- the DNA aptamer can also be used as the aptamer itself, but if necessary, at the 5'end or 3'end, it has its own primary structure and its own primary structure against degradation by enzymatic degradation or physical stimuli such as light and heat.
- Aptamers with oligonucleic acids added that have other functions such as protecting and stabilizing secondary and three-dimensional structures, PEG (polyethylene glycol)-and glycosylated modifiers, drug complexes, antibodies -It can also be used as a modified product such as an aptamer complex, a homopolyvalent aptamer such as antibody, and a hetero-polyvalent aptamer such as polyethylene.
- the DNA aptamer produced by introducing the artificial base of the present embodiment is a specific human or animal drug or raw material thereof, medical material, a tool for drug delivery, a specific example as exemplified by affinity column chromatography. It can be used as a tool or module for substance or cell separation / purification, a sensor for detecting a specific substance, an additive for health foods, or a diagnostic reagent.
- affinity column chromatography a substance selectively bound to a DNA aptamer can be separated by binding a DNA aptamer to a carrier and providing a sample to the column chromatography provided with the carrier.
- Apheresis is a specific example of the application of affinity column chromatography to medical materials or medical devices.
- nucleic acid refers to a biopolymer in which a plurality of nucleotides are linked via a phosphodiester bond.
- DNA refers to a biopolymer in which deoxyribonucleotides are linked via a phosphodiester bond.
- a part of the phosphate diester bond between nucleotides may be a modified phosphate such as phosphorothioate.
- nucleic acid includes single-stranded or double-stranded DNA.
- the "nucleic acid”, “oligonucleic acid” or “nucleic acid molecule” herein may form a triple or quadruplex, and in some cases, a chimeric molecule of DNA and RNA. There may be.
- the 2'-position of deoxyribose or ribose forming a nucleoside may be modified with fluorine, a methoxy group or the like.
- 2-Bromothiophene (50.0 g, 307 mmol) was dissolved in tetrahydrofuran (700 ml) under an argon atmosphere and cooled in a dry ice / acetone bath (internal temperature ⁇ 60 ° C.). Tetramethylethylenediamine (55.5 ml, 368 mmol) was added, a 1.1 M n-hexane / tetrahydrofuran solution (355 ml, 368 mmol) of lithium diisopropylamide was added dropwise while keeping the internal temperature below ⁇ 55 ° C., and the mixture was stirred as it was for 1 hour. ..
- Example 1 a deoxynucleoside (compound 1) containing a base having a benzyl group at the 5-position of thiophene of Ds was synthesized, but another 5-position of thiophene of Ds was synthesized by the same method as the synthesis of compound 1.
- Deoxynucleosides with functional groups can be synthesized.
- Example 2 a 3'-phosphoromidite of a deoxynucleoside containing a base having a benzyl group at the 5-position of thiophene of Ds was synthesized, but another functional group was synthesized at the 5-position of thiophene of Ds by the same method. 3'-Phosphoramidite of the deoxynucleoside having the above can be synthesized.
- Example 3 5'-triphosphate of a deoxynucleoside containing a base having a benzyl group at the 5-position of thiophene of Ds was synthesized.
- 5'-triphosphate of deoxynucleoside having another functional group at the 5-position of thiophene of Ds can be synthesized.
- Triphenylphosphine (123.57 g, 471 mmol) was added to bromocyclopentane (78.0 g, 523 mmol) under an argon atmosphere, the mixture was heated to 135 to 140 ° C., and the mixture was stirred as it was for 4.5 hours. After cooling to 40 ° C., toluene (100 mL) was added, the solid was filtered, the filtered solid was washed with toluene, dried under reduced pressure, and cyclopentyltriphenylphosphonium bromide (135.9 g, 82 wt%, yield: 57.5%).
- reaction suspension After stirring for 15 minutes after all NaH has been added, the reaction suspension is cooled to 30 ° C., poured into ice water (4 L), extracted twice with ethyl acetate (2 L) and the organic layer is 20%-. After washing with a saline solution, the mixture was concentrated under reduced pressure. Heptane (500 mL) was added to the concentrated residue and suspended (ultrasound), and the suspension was filtered. The filtrate was washed with heptane and the filtrate was concentrated under reduced pressure. The concentrated residue was purified by column chromatography (silica gel, 1 kg, heptane) to obtain 2-bromo-5- (cyclopentylidenemethyl) thiophene (34.2 g, 67.3%).
- the reaction mixture was then cooled and poured into a mixed solvent of water (500 mL) -heptane (300 mL) -ethyl acetate (300 mL) and the insoluble material filtered.
- the organic layer was separated and the aqueous layer was extracted again with heptane (200 mL) -ethyl acetate (200 mL).
- the organic layer was washed with saturated brine (400 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a crude product (82.9 g).
- Heptane (300 mL) was added, and concentration under reduced pressure was performed again.
- the reaction mixture was returned to room temperature, poured into water (500 mL) -ethyl acetate (500 mL), and the insoluble material was filtered through cerite. The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (500 mL). The organic layer was washed with saturated brine (300 mL) (again, insoluble material was filtered), dried over sodium sulfate, and concentrated under reduced pressure to obtain a crude product (44.3 g).
- the obtained 4- [5- (cyclopentylidenemethyl) -2-thienyl] -3-nitro-pyridine-2-amine (impure) was divided into two, and each was again subjected to column chromatography (silica 200 g, chloroform: acetate).
- lithium diisopropylamide (1.08 M n-hexane / tetrahydrofuran solution, 50.0 mL, 54.1 mmol, 1.2 eq.
- lithium diisopropylamide 50.0 mL, 54.1 mmol, 1.2 eq.
- a solution of 2-Bromomethyl naphthalene (12.0 g, 54.1 mmol, 1.2 eq.) In tetrahydrofuran (20 mL) was added dropwise, the mixture was pulled up from a dry ice / acetone bath, heated to room temperature, and then stirred for 19 hours.
- Example 1 [(2R) -3- (4-methylbenzoyl) oxy-5- [7- [5- (2-naphthylmethyl) -2-thienyl] produced in step 4 in the same manner as in step 7. ]
- nucleoside 3'-amidite containing an artificial base of the present embodiment is used in a commonly used solid phase synthesis method. It can be used for the synthesis of oligonucleic acid under the same conditions as the natural base nucleoside 3'-amidite.
- Compound 2 was applied to a solid phase synthesis method, and the obtained DNA strand was purified by polyacrylamide gel electrophoresis. As a result of analyzing the mass of the purified DNA chain by the MS spectrum, it was confirmed that the molecular weight was 31850.2 (theoretical value: 3185.29) and that the DNA containing the target Dsbn was obtained.
- nucleoside 5'-triphosphate having an artificial base Application of nucleoside 5'-triphosphate having an artificial base to PCR
- the artificial base 7- (5-benzyl-2-thienyl) -3H-imidazole [4,5-b] -pyridine-3-yl is used as a base.
- the DNA fragment obtained by PCR was analyzed by LC / MS in order to confirm that the nucleotide (hereinafter referred to as dDsbn) contained in the portion was incorporated into the DNA strand by DNA polymerase and amplified.
- the single-stranded DNA containing dDsbn prepared in Example 8 was used as a template for the following PCR.
- PCR was performed with AkcuPrime Pfx DNA polymerase (manufactured by Thermo Fisher Scientific).
- the composition of the solution for PCR is 1xAccuPrime Pfx Reaction Mix (including dNTP 0.3 mM, 1.0 mM ⁇ 4 ), 0.5 mM ⁇ 4 , 0.1 mM dNTP, 0.5 ⁇ M Forward Primer (see below for sequence), 0.5 ⁇ M Reverse Primer (see sequence below), 0.05 mM dDsbnTP, 0.05 mM diol1-dPxTP (1- (2-deoxy- ⁇ -D-ribofuranosyl) -4-[(4-pentin-1,2-diol) ) -1-Propinyl] -2-nitropyrrole-5'triphosphate), 0.05 unit / ⁇ L AccuPrime Pfx DNA polymerase.
- the retention time of the main component of the 60 cycle PCR product was 4.44 seconds, and the measured molecular weight was 31836.2.
- the data are shown in Table 1.
- the retention time of the main component contained in each DNA product obtained from 20, 40, and 60 cycles is almost the same as the control, and the molecular weight of the measured value is 0.05% different from the theoretical value.
- dDsbn of the present embodiment was recognized by DNA polymerase and incorporated into the replicated DNA fragment by PCR.
- Example 10 Screening using a single-stranded DNA library containing a nucleoside with an artificial base ⁇ Acquisition of DNA aptamer for VEGF165>
- the single-stranded DNA library containing dDsbn used in the screening was synthesized by a chemical synthesis method, and the obtained DNA was purified by polyacrylamide gel electrophoresis.
- a single-stranded DNA library containing dDsbn in a random region was dissolved in PBS solution and a folding operation (95 ° C., 5 minutes ⁇ room temperature, 20 minutes ⁇ on ice, 5 minutes) was performed to form tertiary structure. did. Then, a PBS solution containing NP-40 was added, and the solution composition was prepared to a PBS solution (binding solution) containing 0.005% NP-40. Then, the target protein VEGF 165 was added, and the mixture was inverted and mixed at room temperature for 30 minutes.
- Ez-Link Sulfo-NHS-Lc-biotin manufactured by Thermo Fisher Scientific
- glycine was added to terminate the reaction.
- Amicon UltraFilter-0.5 50k manufactured by MERCK
- PCR was performed using the AcuPrime Pfx DNA polymerase to amplify the recovered single-stranded DNA pool.
- the composition of the PCR reaction solution is 1x AccuPrime Pfx Reaction Mix (including dNTP 0.3 mM, 1.0 mM ⁇ 4 ), 0.5 mM ⁇ 4 , 0.1 mM dNTP, 0.5 ⁇ M Forward Primer for selection (sequence is as follows). See), Reverse Primer for 0.5 ⁇ M selection (see below for sequence), 0.05 mM dDsbnTP, 0.05 mM diol1-dPxTP, 0.05 unit / ⁇ L AccuPrime Pfx DNA polymerase.
- the PCR cycle conditions are 94 ° C., 2 minutes- (94 ° C., 15 seconds-65 ° C., 210 seconds) x n cycles.
- the number of cycles n was different for each round, but the number of cycles required to amplify to an amount that could be purified by polyacrylamide gel electrophoresis was performed.
- Purification of the single-stranded DNA pool from the amplified DNA fragment is performed by 10% polyacrylamide gel electrophoresis containing 7M urea, and the DNA fragment is extracted from the gel piece containing the DNA fragment and desalted. Ethanol precipitation was performed on the subject to purify the single-stranded DNA pool that binds to the target protein. By repeating this operation under the conditions of changing the concentration of the single-stranded DNA pool and the target protein and the washing step, the concentration of the sequence bound to the target protein was promoted.
- the magnetic beads are added to the pool after the folding operation and mixed by inversion for 30 minutes at room temperature.
- the target protein was added to the pool solution from which the magnetic beads had been removed and reacted.
- EMSA electrospray assay
- a single-stranded DNA pool was prepared in a binding solution to 0.2 ⁇ M and folded (95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.) to form tertiary structure. rice field.
- the target protein was diluted with a binding solution to a predetermined concentration, mixed with the folded DNA solution, and kept warm at 37 ° C. for 30 minutes. The sample after heat insulation was run on a 10% undenatured polyacrylamide gel.
- a next-generation sequencer (Ion PGM system, manufactured by Thremo fisher) was used to analyze the sequences contained in the DNA pool obtained by screening. As a result of clustering the sequence group in which the inserted base length between the Forward primer for selection and the Reverse Primer for selection did not change and the artificial base dDsbn remained, a single sequence occupied about 80%.
- the oligomer corresponding to the candidate sequence was synthesized by a chemical synthesis method and purified by OPC (cartridge).
- the purified candidate sequence oligomer (T-00199, sequence see below) was prepared in the binding solution to 0.2 ⁇ M and folded (95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25. °C) was carried out to form a tertiary structure.
- VEGF165 was diluted with a binding solution to 0.2 ⁇ M, mixed with the folded DNA solution, and kept warm at 37 ° C.
- a next-generation sequencer (Ion PGM system) was used to analyze the sequences contained in the DNA pool obtained by screening. As a result of clustering the sequence group in which the inserted base length between the Forward primer for selection and the Reverse Primer for selection did not change and the artificial base dDsbn remained, the most abundant single sequence was about 8%. there were.
- EMSA ⁇ Evaluation of binding affinity of candidate sequence to target protein by EMSA> Whether or not the most concentrated candidate sequence binds to the target protein was analyzed by EMSA.
- an oligomer corresponding to the candidate sequence (T-00202, sequence see below) was synthesized by a chemical synthesis method, and purified by OPC (cartridge).
- the purified candidate sequence oligos are prepared in the binding solution to 0.2 ⁇ M, and the folding operation (95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.) is performed to carry out the tertiary structure.
- the folding operation 95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.
- the sIL-6R was then diluted to 0.2 ⁇ M with the binding solution, mixed with the folded DNA solution and kept warm at room temperature for 30 minutes.
- the sample after heat insulation was run on an 8% undenatured polyacrylamide gel, and it was analyzed whether the band of the DNA-protein complex could be detected.
- DNA was stained with SYBR Gold and detected by blue light at 470 nm (2 lanes on the left side of FIG. 4). As a result, a new band was detected in the presence of sIL-6R, and it was clarified that the sequence identified in this screening is an aptamer that binds to sIL-6R.
- nucleoside 3'-amidite containing an artificial base of the present embodiment is used in a commonly used solid phase synthesis method. It can be used for the synthesis of oligonucleic acid under the same conditions as the natural base nucleoside 3'-amidite.
- Compound 3 was applied to the solid phase synthesis method, and the obtained DNA strand (T-00243, see below for the sequence) was purified by polyacrylamide gel electrophoresis. The inclusion of dDscp in the synthesized DNA strand was analyzed using a next-generation sequencer (Ion PGM system).
- Example 12 Application of nucleoside 5'-triphosphate with artificial base to PCR Artificial base 7- (5-cyclopentylmethylthiophene-2-yl) -3H-imidazole [4,5-b] pyridine-3-yl (
- dDscp nucleotide having Dsc () as a base portion
- the DNA fragment obtained by PCR was analyzed by a next-generation sequencer.
- the single-stranded DNA (T-00243) containing dDscp prepared in Example 11 was used as a template DNA for the following PCR reaction.
- PCR was performed with AccuPrime Pfx DNA polymerase.
- the composition of the solution for PCR is 1xAccuPrime Pfx Reaction Mix (including dNTP 0.3 mM, 1.0 mM ⁇ 4 ), 0.5 mM ⁇ 4 , 0.1 mM dNTP, 0.5 ⁇ M Forward Primer, 0.5 ⁇ M Reverse Primer, 0. .05 mM dDscpTP, 0.05 mM diol1-dPxTP, 0.05 unit / ⁇ L AccuPrime Pfx DNA polymerase.
- 4.8x10 9 molecules of single-stranded DNA T-00243 were added to the reaction solution having this composition, and PCR was carried out at 94 ° C.
- the product was prepared.
- the obtained PCR product was purified by polyacrylamide gel electrophoresis, and a single-stranded DNA fragment corresponding to the template DNA was isolated. Using the isolated and purified single-stranded DNA, amplification and purification of the DNA fragment were repeated under the above-mentioned PCR conditions to prepare a single-stranded DNA that had been subjected to a total of 60 cycles.
- Example 13 Screening using a single-stranded DNA library containing a nucleoside with the artificial base dDscp ⁇ Acquisition of DNA aptamers for VEGF165>
- the single-stranded DNA library containing dDscp used in the screening was synthesized by a chemical synthesis method, and the obtained DNA was purified by polyacrylamide gel electrophoresis.
- This single-stranded DNA library was different from the Primer combination used in Example 10, and used Forward Primer 2 and Reverse Primer 2 for selection (see below for the sequence).
- the step of concentrating the binding sequence to VEGF165 using a single-stranded DNA library containing dDscp in a random region was carried out in the same procedure as the screening method shown in Example 6.
- the DNA pool obtained in the screening step was evaluated by EMSA to see if it contained a DNA sequence that binds to VEGF165.
- a folding operation was performed to form a three-dimensional structure, and VEGF165 was diluted with a binding solution to a predetermined concentration. Each was mixed, kept warm at 37 ° C. for 30 minutes and analyzed on an 8% undenatured polyacrylamide gel (FIG. 5). As a result, a clear shift band bound to VEGF165 was detected in the DNA pool of the final round, and it was clear that the DNA pool obtained by screening was enriched with the DNA sequence binding to VEGF165. became.
- a next-generation sequencer (Ion PGM system) was used to analyze the sequences contained in the DNA pool obtained by screening. As a result of clustering the sequence group in which the inserted base length between Forward primer2 for selection and Reverse Primer2 for selection did not change and the artificial base dDscp remained, the most abundant single sequence was about 30%. there were.
- EMSA ⁇ Evaluation of binding affinity of candidate sequence to target protein by EMSA> Whether or not the most concentrated candidate sequence binds to the target protein was analyzed by EMSA.
- an oligomer (T-00244, sequence see below) corresponding to the candidate sequence was synthesized by a chemical synthesis method, and purified by OPC (cartridge).
- the purified candidate sequence oligos are prepared in the binding solution to 0.2 ⁇ M, and the folding operation (95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.) is performed to carry out the tertiary structure.
- the folding operation 95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.
- VEGF165 was then diluted to 0.2 ⁇ M with the binding solution, mixed with the folded DNA solution and kept warm at 37 ° C. for 30 minutes. The sample after heat insulation was run on an 8% undenatured polyacrylamide gel, and it was analyzed whether the band of the DNA-protein complex could be detected. DNA was stained with SYBR Gold and detected with 470 nm blue light. As a result, a new band was detected in the presence of VEGF165 (two lanes on the left side of FIG. 6), indicating that the sequence identified in this screening is an aptamer that binds to VEGF165.
- the DNA pool obtained in the screening step was evaluated by EMSA to see if it contained a DNA sequence that binds to sIL-6R.
- a folding operation was performed to form a three-dimensional structure, and sIL-6R was diluted with a binding solution to a predetermined concentration. Each was mixed, kept warm at room temperature for 30 minutes and analyzed on an 8% undenatured polyacrylamide gel (FIG. 7). As a result, a clear shift band bound to the increased concentration of sIL-6R was detected in the DNA pool of the final round, and the DNA sequence obtained by screening had a DNA sequence that binds to sIL-6R. Was found to be concentrated.
- a next-generation sequencer (Ion PGM system) was used to analyze the sequences contained in the DNA pool obtained by screening. As a result of clustering a group of sequences in which the inserted base length between Forward primer2 for selection and Reverse Primer2 for selection did not change and the artificial base dDscp remained, a single sequence having a high abundance ratio of about 22% was identified.
- EMSA ⁇ Evaluation of binding affinity of candidate sequence to target protein by EMSA> Whether or not the most concentrated candidate sequence binds to the target protein was analyzed by EMSA.
- an oligomer (T-00247, sequence see below) corresponding to the candidate sequence was synthesized by a chemical synthesis method, and purified by OPC (cartridge).
- the purified candidate sequence oligos are prepared in the binding solution to 0.2 ⁇ M, and the folding operation (95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.) is performed to carry out the tertiary structure.
- the folding operation 95 ° C., 5 minutes ⁇ (-0.1 ° C./sec) ⁇ 25 ° C.
- the sIL-6R was then diluted to 0.6 ⁇ M with the binding solution, mixed with the folded DNA solution and kept warm at room temperature for 30 minutes.
- the sample after heat insulation was run on an 8% undenatured polyacrylamide gel, and it was analyzed whether the band of the DNA-protein complex could be detected.
- DNA was stained with SYBR Gold and detected with 470 nm blue light. As a result, a new band was detected in the presence of sIL-6R (2 lanes on the left side of FIG. 8), demonstrating that the sequence identified in this screening is an aptamer that binds to sIL-6R. rice field.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)DNAの場合、構成単位である核酸塩基が、汎用されるのは天然型の4種(A、T、G、C)に限られている。このため、天然型アミノ酸が20種存在することと比較すると、天然型核酸塩基は相互作用を形成するための構成単位が少ないため、それに伴い、相互作用が形成される組み合わせの種類も乏しい。
(2)DNAの場合、天然型の4種の核酸塩基の塩基部分が、タンパク質等のターゲット分子と直接相互作用するのに用いられるが、天然型の塩基部分の構造は柔軟性に乏しく、脂溶性もそれほど大きくないことから、脂溶性相互作用を期待する部分構造としては適切とはいえない。
(3)DNAを含むオリゴ核酸は、リン酸結合部分に負電荷を持つ。このためオリゴ核酸は、負電荷を持ったターゲット分子とは静電反発が生じることから相互作用しにくく、アプタマーのターゲットにできる分子の種類に制限がある。
(1)DNAまたはオリゴ核酸のユニットとして化学合成で使用可能である。
(2)PCRで増幅可能である。
(3)ターゲット分子とフレキシブルに適切な相互作用できる部分構造を有する。
(4)ターゲット分子と相互作用する条件下で正電荷をもつ部分構造を有する。
・ターゲット分子とのより効果的な疎水性相互作用を形成することによる親和性の向上。
・分子全体の脂溶性の向上で水溶性が低下することによる、水中でのターゲット分子との複合体の形成促進。
・従来、DNAアプタマーが結合しにくいとされてきた負電荷を持つターゲット分子についても、適切な相互作用が期待でき、アプタマーの取得の可能性が向上する。
・従来、アプタマーを取得しにくいとされてきた糖鎖についても、アプタマー取得の可能性が向上する。
本実施形態に係る人工塩基は、2-アミノ-3-ニトロ-4-クロロピリジンとのカップリング反応を行う工程を含む方法により合成することができる。当該カップリング反応を、鈴木カップリング反応条件で行うことにより、汎用されているスズ含有中間体を用いることなくカップリング反応を行うことができる。これにより、スズを含む廃棄物を排出させることがないため、スズ含有中間体を用いる従来法と比較して環境負荷を小さくした合成法とすることができる。また、スケールアップした合成を可能とすることができる。
本実施形態の人工塩基を有するヌクレオシドの5´-水酸基を適切な保護基で保護した3´-ホスホロアミダイトは、天然塩基と同様の条件下で固相合成法により、DNAまたはオリゴ核酸の構成要素としてDNAの化学合成に使用することができる。具体的には、本実施形態に係る人工塩基を有するヌクレオシドの5´-水酸基保護-3´-ホスホロアミダイトを、天然型または修飾ヌクレオシドホスホロアミダイトと組み合わせて、汎用されるDNAの化学合成装置によって所望の鎖長を有するDNAを合成することができる。
本実施形態の人工塩基を有するヌクレオチドは、相補的人工塩基Pxと塩基対を形成することが可能であるため、PCRで機能する。すなわち、PCR溶液に本実施形態の人工塩基を有するヌクレオシドの5´-三リン酸とともにPxを有するヌクレオシドの5´-三リン酸を添加しておくことで、本実施形態の人工塩基とPxとが塩基対を形成した二本鎖DNAがPCRによって増幅される。よって、PCRが必要なSELEX法でのアプタマーのスクリーニングに使用することができる。PCRでの増幅によるDNA合成時の人工塩基の導入の数は、1つのDNA中に1~5個が適当であり、好ましくは3個以下である。また、1つのDNA中に複数個の人工塩基を含む場合には、1つのDNA中に含まれる人工塩基が同じものであってもよく、別の塩基対を形成する人工塩基を含めることとしてもよい。また、同じ一本鎖の中で塩基対を形成し、二次構造や三次構造を形成してもよい。
7-(5-ベンジルチオフェン-2-イル)-3-(2-デオキシ-1-β-D-リボフラノシル)-3H-イミダゾ[4,5-b]ピリジン(化合物1)の合成
<工程1:2-ブロモ-5-ベンジルチオフェンの合成>
1H-NMR(CDCl3,400MHz)δ(ppm):4.06(s,2H),6.54-6.55(m,1H),6.85(d,J=3.7Hz,1H),7.21-7.25(m,3H),7.28-7.33(m,2H).
1H-NMR(CDCl3,400MHz)δ(ppm):1.31(s,12H),4.18(s,2H),6.87-6.89(m,1H),7.19-7.31(m,5H),7.47(2.3Hz,1H).
1H-NMR(CDCl3,400MHz)δ(ppm):4.16(s,2H),5.63(bs,2H),6.72(d,J=5.0Hz,1H),6.76-6.78(m,1H),6.97(d,J=3.7Hz)7.26-7.35(m,5H),8.12(d,J=5.5Hz,2H).
原料の消失を確認し、Ar置換を行った後にセライト濾過を行い、残渣をメタノールで洗い込んだ。ろ液を減圧下濃縮することにより2,3-ジアミノ-4-(5-ベンジルチオフェン-2-イル)ピリジン(10.1g)を黒褐色油状物質として得た。
1H-NMR(CDCl3,400MHz)δ(ppm):3.79(bs,2H),4.16(s,2H),4.42(bs,2H),6.68(d,J=5.0Hz,1H),6.81-6.83(m,1H),7.05(d,J=3.7Hz,1H),7.23-7.35(m,5H),7.57(d,J=5.5Hz,1H).
1H-NMR(DMSO-d6,400MHz)δ(ppm):4.23(s,2H),7.04(d,J=4.1Hz,1H),7.23-7.26(m,1H),7.32-7.37(m,4H),7.45(d,J=5.0Hz,1H),8.09(d,J=3.7Hz,1H),8.27(d,J=5.0Hz,1H),8.43(s,1H).
1H-NMR(CDCl3,400MHz)δ(ppm):2.38(s,3H),2.44(s,3H),2.85(ddd,J=14.2Hz,5.5Hz,1.8Hz,1H),3.16-3.19(m,1H),4.21(s,1H),4.64-4.77(m,3H),5.83(d,J=5.9Hz,1H),6.68(dd,J=8.5Hz,5.7Hz,1H),6.89(d,J=3.7Hz,1H),7.19-7.34(m,9H),7.38(d,J=5.0Hz,1H),7.90(d,J=8.2Hz,2H),7.98-7.99(m,3H),8.25(s,1H),8.29(d,J=5.0Hz,1H).
1H-NMR(DMSO-d6,400MHz)δ(ppm):2.34(ddd,J=13.2Hz,6.0Hz,3.0Hz,1H),2.75-2.82(m,1H),3.52-3.57(m,1H),3.63-3.66(m,1H),3.91(dd,J=7.3Hz,4.6Hz,1H),4.23(s,2H),4.44-4.46(m,1H),5.12(t,J=5.7Hz),5.34(d,J=3.7Hz),6.52(t,J=7.3Hz,1H),7.05(d,J=3.7Hz,1H),7.24-7.26(m,1H),7.32-7.37(m,4H),7.54(d,J=5.5Hz),8.12(d,J=3.7Hz),8.30(d,J=5.0Hz,1H),8.70(s,1H).
7-(5-ベンジルチオフェン-2-イル)-3-[2-デオキシ-5-O-(4,4´-ジメトキシトリチル)-1-β-D-リボフラノシル]-3H-イミダゾ[4,5-b]ピリジン 2-シアノエチル-N,N´-ジイソプロピルホスホロアミダイト(化合物2)の合成
<工程1:7-(5-ベンジルチオフェン-2-イル)-3-[2-デオキシ-5-O-(4,4´-ジメトキシトリチル)-1-β-D-リボフラノシル]-3H-イミダゾ[4,5-b]ピリジンの合成>
Mass: ESI(-) 708.28
7-(5-ベンジルチオフェン-2-イル)-3-(2-デオキシ-1-β-D-リボフラノシル)-3H-イミダゾ[4,5-b]ピリジン 5´-トリフォスフェートの合成
Mass: ESI(-) 646.21
7-(5-シクロペンチルメチルチオフェン-2-イル)-3-(2-デオキシ-1-β-D-リボフラノシル)-3H-イミダゾ[4,5-b]ピリジン(化合物3)の合成
<工程1:2-ブロモ-5-(シクロペンチリデンメチル)チオフェンの合成>
アルゴン雰囲気下、2-ブロモー4-ホルミルチオフェン(40.0g,209mmol)をTHF(1L)に溶解し、シクロペンチルトリフェニルフォスフォニウムブロミド(126g,251mmol)のTHF(1L)溶液を加えた。反応懸濁液を60℃に加熱し、NaH(1.26g,26.2mmol,60wt%品)を15分間隔で25回添加した(合計添加量31.5g、655mmol)。すべてのNaHを添加し終えてから15分攪拌した後に、反応懸濁液を30℃まで冷却し、氷水(4L)に注ぎ、酢酸エチル(2L)で2回抽出し、有機層を20%-食塩水で洗浄後、減圧濃縮した。濃縮残渣にヘプタン(500mL)を加え懸濁させ(超音波)、懸濁物を濾過した。濾過物をヘプタンで洗浄し、濾液を減圧濃縮した。濃縮残渣をカラムクロマトグラフィー(シリカゲル、1kg、ヘプタン)で精製し、2-ブロモー5―(シクロペンチリデンメチル)チオフェン(34.2g,67.3%)を得た。
1H-NMR(CDCl3,400MHz) δ(ppm):1.65-1.72(m,2H),1.80-1.87(m,2H),2.40-2.46(m,4H),6.47-6.48(m,1H),6.61(d,J=3.7Hz,1H),6.93(d,J=4.1Hz,1H)
1H-NMR(CDCl3,400MHz) δ(ppm):1.34(s,12H),1.65-1.72(m,2H),1.80-1.86(m,2H),2.46-2.55(m,4H),6.64(m,1H),6.94(d,J=3.7Hz,1H),7.53(d,J=3.7Hz,1H)
1H-NMR(CDCl3,400MHz) δ(ppm):1.68-1.75(m,2H),1.82-1.89(m,2H),2.48-2.55(m,4H),3.77(bs,2H),4.25(bs,2H),6.59(t,J=2.3Hz,1H),6.77(d,J=5.5Hz,1H),6.91(d,J=3.7Hz,1H),7.15(d,J=3.7Hz,1H),7.65(d,J=5.0Hz,1H)
1H-NMR(CDCl3,400MHz) δ(ppm):1.22-1.31(m,2H),1.52-1.60(m,2H),1.62-1.70(m,2H),1.77-1.87(m,2H),2.15-2.26(m,2H),2.31(dd,J=5.7,13.5Hz,1H),2.88(d,J=7.3Hz,2H),3.20-3.27(m,1H),3.81(t,J=12.3Hz,1H),4.00(d,J=12.8,1H),4.26(s,1H),4.83(d,J=4.1Hz,1H),6.43(dd,J=5.5,9.6Hz,1H),6.80(d,J=11.4Hz,1H),6.89(d,J=3.7Hz,1H),7.44(d,J=5.5Hz,1H),8.00(d,J=3.7Hz,1H),8.12(s,1H),8.25(d,J=5.5Hz,1H)
Mass: ESI(-) 638.10
7-(2-ナフチルメチルチオフェン-2-イル)-3-(2-デオキシ-1-β-D-リボフラノシル)-3H-イミダゾ[4,5-b]ピリジン(化合物4)の合成
<工程1:2-ブロモー5-(2-ナフチルメチル)チオフェンの合成>
原料の消失を確認後、飽和塩化アンモニウム水溶液(100mL)及び酢酸エチル(100mL)を加えて分液し、水層を酢酸エチル(100mL)で再抽出した。有機層を合わせ、飽和食塩水(100mL)で洗浄した後、無水硫酸ナトリウムで乾燥し、ろ過した。ろ液を減圧下濃縮することで、褐色固体(21.0g)を得た。シリカゲルカラムクロマトグラフィー(富士シリシア SI50 SIZE200×4;n-ヘプタン)により精製し、目的物のフラクションを減圧下濃縮することで、2-ブロモ-5-(2-ナフチルメチル)チオフェン(4.27g,収率31%)を白色固体として取得した。
1H-NMR(CDCl3,400MHz) δ(ppm):4.23(s,2H),6.59-6.61(m,1H),6.88(d,J=3.6Hz,1H),7.35(dd,J=1.8,8.2Hz,1H),7.43-7.49(m,2H),7.67(s,1H),7.78-7.83(m,3H)
1H-NMR(CDCl3,400MHz) δ(ppm):1.31(s,12H),4.34(s,2H),6.92-6.93(m,1H),7.37(dd,J=1.8,8.6Hz,1H),7.42-7.49(m,3H),7.69(s,1H),7.76-7.81(m,3H)
1H-NMR(CDCl3,400MHz) δ(ppm):2.41(s,3H),2.45(s,3H),2.85(ddd,J=2.2,5.6,14.1Hz,1H),3.08-3.19(m,1H),4.63-4.92(m,3H),5.83(dt,J=1.8,6.0Hz,1H),6.65(dd,J=5.8,8.0Hz,1H),7.18-7.30(m,5H),7.90(d,J=8.0Hz,2H),7.98(d,J=8.0Hz,2H),8.26-8.27(m,2H)
1H-NMR(CDCl3,400MHz) δ(ppm):2.38(s,3H),2.44(s,3H),2.85(ddd,J=2.2,5.6,14.1Hz,1H),3.14-3.21(m,1H),4.38(s,2H),4.66-4.76(m,3H),5.83(dt,J=1.8,6.0Hz,1H),6.68(dd,J=5.8,8.2Hz,1H),6.94(d,J=4.0Hz,1H),7.20(d,J=8.4Hz,2H),7.28(d,J=8.4Hz,2H),7.38-7.49(m,4H),7.74-7.83(m,4H),7.91(d,J=8.4Hz,2H),7.98(d,J=8.0Hz,2H),8.01(d,J=4.0Hz,1H),8.25(s,1H),8.29(d,J=5.2Hz,1H)
1H-NMR(CDCl3,400MHz) δ(ppm):1.89(s,1H),2.31(dd,J=5.2,14.1Hz,1H),3.20-3.27(m,1H),3.78-3.84(m,1H),3.98-4.01(m,1H),4.25(s,1H),4.38(s,2H),4.83(t,J=4.0Hz,1H),6.42(dd,J=5.6,10.0Hz,1H),6.69-6.72(m,1H),6.94-6.96(m,1H),7.40-7.49(m,4H),7.75(s,1H),7.79-7.83(m,3H),8.03(d,J=3.6Hz,1H),8.10(s,1H),8.24(d,J=5.2Hz,1H)
人工塩基を有するヌクレオシドの3´-アミダイトを用いたDNAの合成
化合物2を一例とする、本実施形態の人工塩基を含んだヌクレオシド3´-アミダイトは、一般的に用いられる固相合成法において、天然塩基のヌクレオシド3´-アミダイトと同等な条件でオリゴ核酸の合成に使用可能である。化合物2を固相合成法に適用し、得られたDNA鎖をポリアクリルアミドゲル電気泳動によって精製した。精製したDNA鎖の質量をMSスペクトルにて解析した結果、分子量が31850.2(理論値:31852.9)であり、目的とするDsbnを含むDNAが得られたことを確認できた。
人工塩基を有するヌクレオシド5´-三リン酸のPCRへの適用
人工塩基である7-(5-ベンジル-2-チエニル)-3H-イミダゾ[4,5-b]-ピリジン-3-イルを塩基部分にもつヌクレオチド(以下、dDsbnと称する)がDNAポリメラーゼによってDNA鎖に取り込まれ、かつ増幅することを確認するため、PCRによって得られたDNA断片をLC/MSで解析した。
実施例8で調製したdDsbnを含む一本鎖DNAを以下のPCRの鋳型として用いた。
PCRは、AccuPrime Pfx DNA polymerase(Thermo Fisher Scientific社製)で行った。PCR用溶液の組成は、1xAccuPrime Pfx Reaction Mix(dNTP 0.3mM,1.0mM MgSO4を含む),0.5mM MgSO4,0.1mM dNTP,0.5μM Forward Primer(配列は下記を参照),0.5μM Reverse Primer(配列下記参照),0.05mM dDsbnTP,0.05mM diol1-dPxTP(1-(2-デオキシ-β-D-リボフラノシル)-4-[(4-ペンチン-1,2-ジオール)-1-プロピニル]-2-ニトロピロール-5´ トリホスフェート),0.05unit/μL AccuPrime Pfx DNA polymeraseである。この組成の反応液中に一本鎖DNA(T-00198、配列下記参照)を4.8x109分子添加して、94℃、2分-(94℃、15秒-65℃、210秒)×20サイクルでPCR産物を調製した。得られたPCR産物はポリアクリルアミドゲル電気泳動で精製し、鋳型DNAに相当する一本鎖DNA断片を単離した。単離精製した一本鎖DNAを用いて、上述のPCR条件でDNA断片の増幅および精製を繰り返し、トータル100サイクルさせた一本鎖DNAを調製した。
A(100mM 1,1,1,3,3,3-Hexafluoro-2-propanol, 8mM triethylamine)移動相B(アセトニトリル)を使用した。移動相を0.2mL/minで流し、移動相Bを10分間で10%から50%になるようなグラジェントをかけて分析した。その時のカラム温度は60℃であり、260nmの波長(Acquity UPLC PDA)で検出した。DeconvolutionはProMassを使用して解析を行った。
人工塩基を有するヌクレオシドを含む一本鎖DNAライブラリーを用いたスクリーニング
<VEGF165に対するDNAアプタマーの取得>
スクリーニングで使用する、dDsbnが含まれる一本鎖DNAライブラリーは、化学合成法により合成し、得られたDNAをポリアクリルアミドゲル電気泳動によって精製した。
この操作を、一本鎖DNAプールと標的タンパク質の濃度や、洗浄工程を変えた条件を繰り返し行うことで、標的タンパク質に結合する配列の濃縮を進めた。2回目のラウンド以降では、ストレプタアビジン磁気ビーズに非特異的に結合してしまう一本鎖DNAプールの排除のために、フォールディング操作後のプールに磁気ビーズを加えて、室温で30分間転倒混和をし、磁気ビーズを除去したプール溶液に標的タンパク質を加えて反応させた。
標的タンパク質に結合する一本鎖DNAの濃縮させたプールを用いて、標的タンパク質とのEMSA(electrophoretic mobility shift assay)を実施することで、結合する配列が含まれているかを確認した。
一本鎖DNAプールを結合溶液中に0.2μMになるように調製し、フォールディング操作(95℃、5分間→(-0.1℃/秒)→25℃)を行い、三次構造を形成させた。標的タンパク質を結合溶液で所定の濃度に希釈し、フォールディング済みDNA溶液と混ぜて、37℃で30分間保温させた。保温後の試料を10%未変性ポリアクリルアミドゲルで泳動した。泳動後のゲルはSYBR Goldで染色することでDNAを検出した(図1)。その結果、最終ラウンドのプールにて、VEGF165の濃度が高くなるにつれて明確なシフトバンド強度が濃くなり、FreeのDNAバンドが薄くなっていることから、標的タンパク質に結合する配列が存在していることを確認した。
次世代シーケンサー(Ion PGMシステム、Thremo fisher社製)を用いて、スクリーニングで得られたDNAプールに含まれている配列を解析した。セレクション用Forward primerとセレクション用Reverse Primer間の挿入塩基長に変化がなく、さらに人工塩基dDsbnが残存している配列群をクラスタリングした結果、単一配列が約80%程度を占めていた。
同定した候補配列が標的タンパク質に結合するかをEMSAによって解析した。
まず候補配列に相当するオリゴマーを化学合成法で合成し、OPC(カートリッジ)で精製を行った。
精製した候補配列のオリゴマー(T-00199、配列下記参照)を結合溶液中に0.2μMになるように調製し、フォールディング操作(95℃、5分間→(-0.1℃/秒)→25℃)を行うことで、三次構造を形成させた。その後、VEGF165を結合溶液で0.2μMに希釈し、フォールディング済みDNA溶液と混合させ、37℃で30分間保温させた。保温後の試料を未変性10%ポリアクリルアミドゲルで泳動し、DNA-タンパク質複合体のバンドを検出できるかどうかについて分析した。DNAはSYBR Goldで染色させ、470nmのblue lightで検出させた。その結果、VEGF165存在下で、新たなバンドが検出された(図2の左側の2レーン)ことから、本スクリーニングで同定した配列はVEGF165に結合するアプタマーであることを明らかとなった。
上述したVEGF165と同じDsbnを含むDNAライブラリーを用いて、スクリーニング方法も同様な手順で行い、sIL-6Rに結合するDNA配列の濃縮を行った。
スクリーニングを進めて得られたDNAプールにsIL-6Rに結合するDNA配列が含まれているのかどうかを、EMSAで評価した。
立体構造を形成させるためのフォールディング操作を実施し、標的タンパク質sIL-6Rを結合溶液で所定の濃度に希釈した。結合反応は室温で30分間保温し、8%未変性ポリアクリルアミドゲルで解析した(図3)。その結果、最終ラウンドのDNAプールでは、sIL-6R濃度が高くになるについてシフトバンドが濃くなっていることから、このDNAプールにはsIL-6Rに結合するDNA配列が濃縮していることが明らかとなった。
次世代シーケンサー(Ion PGMシステム)を用いて、スクリーニングで得られたDNAプールに含まれている配列を解析した。セレクション用Forward primerとセレクション用Reverse Primer間の挿入塩基長に変化がなく、さらに人工塩基dDsbnが残存している配列群をクラスタリングした結果、最も多く存在していた単一配列は約8%程度であった。
最も多く濃縮していた候補配列が標的タンパク質に結合するかどうかをEMSAによって解析した。
まず候補配列に相当するオリゴマー(T-00202、配列下記参照)を化学合成法で合成し、OPC(カートリッジ)で精製を行った。
精製した候補配列のオリゴを結合溶液中に0.2μMになるように調製し、フォールディング操作(95℃、5分間→(-0.1℃/秒)→25℃)を行うことで、三次構造を形成させた。その後sIL-6Rを結合溶液で0.2μMに希釈し、フォールディング済みDNA溶液と混合させ、室温で30分間保温させた。保温後の試料を8%未変性ポリアクリルアミドゲルで泳動し、DNA-タンパク質複合体のバンドを検出できるかどうかを分析した。DNAはSYBR Goldで染色させ、470nmのblue lightで検出させた(図4の左側の2レーン)。その結果、sIL-6R存在下で、新たなバンドが検出されたことから、本スクリーニングで同定した配列はsIL-6Rに結合するアプタマーであることを明らかとなった。
次に、新規人工塩基dDsbnがsIL-6Rとの結合に関与しているかを確認するために、dDsbnをdDsおよびdAに置換したオリゴ(dDs置換体:T-00203、dA置換体:T-00204、配列下記参照)を用いて評価した。オリゴは化学合成で合成し、OPC(カートリッジ)で精製を実施した。EMSAは上記に示している通りにフォールディング操作、反応、未変性ポリアクリルアミドでの分析を行った(図4)。その結果、dDsbnをdDsおよびdAに置換したことにより、タンパク質との複合体に由来するシフトバンドが消失した。このことより、本実験で同定したdDsbnを含むDNAアプタマーは、標的タンパク質との結合する際に、sIL-6Rと結合するにはdDsbnが重要な働きをしていることを証明できた。
人工塩基を有するヌクレオシドの3´-アミダイトを用いたDNAの合成
化合物3を一例とする、本実施形態の人工塩基を含んだヌクレオシド3´-アミダイトは、一般的に用いられる固相合成法において、天然塩基のヌクレオシド3´-アミダイトと同等な条件でオリゴ核酸の合成に使用可能である。化合物3を固相合成法に適用し、得られたDNA鎖(T-00243、配列は下記を参照)をポリアクリルアミドゲル電気泳動によって精製した。合成したDNA鎖にdDscpが含まれていることは、次世代シーケンサー(Ion PGMシステム)を用いて解析した。
人工塩基を有するヌクレオシド5´-三リン酸のPCRへの適用
人工塩基である7-(5-シクロペンチルメチルチオフェン-2-イル)-3H-イミダゾ[4,5-b]ピリジン-3-イル(Dscp)を塩基部分にもつヌクレオチド(以下、dDscpと称する)がDNAポリメラーゼによってDNA鎖に取り込まれ、かつ増幅することを確認するため、PCRによって得られたDNA断片を次世代シーケンサーで解析した。
実施例11で調製したdDscpを含む一本鎖DNA(T-00243)を以下のPCR反応の鋳型DNAとして用いた。
PCRは、AccuPrime Pfx DNA polymeraseで行った。PCR用溶液の組成は、1xAccuPrime Pfx Reaction Mix(dNTP 0.3mM,1.0mM MgSO4を含む),0.5mM MgSO4,0.1mM dNTP,0.5μM Forward Primer,0.5μM Reverse Primer,0.05mM dDscpTP,0.05mM diol1-dPxTP,0.05unit/μL AccuPrime Pfx DNA polymeraseである。この組成の反応液中に一本鎖DNA(T-00243)を4.8x109分子添加して、94℃、2分-(94℃、15秒-65℃、210秒)×20サイクルでPCR産物を調製した。得られたPCR産物はポリアクリルアミドゲル電気泳動で精製し、鋳型DNAに相当する一本鎖DNA断片を単離した。単離精製した一本鎖DNAを用いて、上述のPCR条件でDNA断片の増幅および精製を繰り返し、トータル60サイクルさせた一本鎖DNAを調製した。
人工塩基dDscpを有するヌクレオシドを含む一本鎖DNAライブラリーを用いたスクリーニング
<VEGF165に対するDNAアプタマーの取得>
スクリーニングで使用する、dDscpが含まれる一本鎖DNAライブラリーは、化学合成法により合成し、得られたDNAをポリアクリルアミドゲル電気泳動によって精製した。この一本鎖DNAライブラリーは、実施例10で使用しているPrimerの組み合わせとは異なり、セレクション用Forwarad Primer 2, Reverse Primer 2(配列は下記を参照)を用いた。
dDscpがランダム領域に含まれる一本鎖DNAライブラリーを用いてVEGF165に対する結合配列の濃縮工程は実施例6に示したスクリーニング方法と同様な手順で実施した。
スクリーニング工程で得られたDNAプールにVEGF165に結合するDNA配列が含まれているかをEMSAで評価した。立体構造を形成させるためのフォールディング操作を実施し、VEGF165は結合溶液で所定の濃度に希釈した。それぞれを混合し、37℃で30分間保温し、8%未変性ポリアクリルアミドゲルで解析した(図5)。その結果、最終ラウンドのDNAプールには、VEGF165と結合した明確なシフトバンドが検出されたことより、スクリーニングで得られたDNAプールにはVEGF165に結合するDNA配列が濃縮していることが明らかとなった。
次世代シーケンサー(Ion PGMシステム)を用いて、スクリーニングで得られたDNAプールに含まれている配列を解析した。セレクション用Forward primer2とセレクション用Reverse Primer2間の挿入塩基長に変化がなく、さらに人工塩基dDscpが残存している配列群をクラスタリングした結果、最も多く存在していた単一配列は約30%程度であった。
最も多く濃縮していた候補配列が標的タンパク質に結合するかどうかをEMSAによって解析した。まず候補配列に相当するオリゴマー(T-00244、配列下記参照)を化学合成法で合成し、OPC(カートリッジ)で精製を行った。精製した候補配列のオリゴを結合溶液中に0.2μMになるように調製し、フォールディング操作(95℃、5分間→(-0.1℃/秒)→25℃)を行うことで、三次構造を形成させた。その後VEGF165を結合溶液で0.2μMに希釈し、フォールディング済みDNA溶液と混合させ、37℃で30分間保温させた。保温後の試料を8%未変性ポリアクリルアミドゲルで泳動し、DNA-タンパク質複合体のバンドを検出できるかどうかを分析した。DNAはSYBR Goldで染色させ、470nmのblue lightで検出させた。その結果、VEGF165存在下で、新たなバンドが検出された(図6の左側の2レーン)ことから、本スクリーニングで同定した配列はVEGF165に結合するアプタマーであることを明らかとなった。
dDscpがランダム領域に含まれる一本鎖DNAライブラリーを用いてsIL―6Rに対する結合配列の濃縮工程は実施例10に示したスクリーニング方法と同様な手順で実施した。
スクリーニング工程で得られたDNAプールにsIL-6Rに結合するDNA配列が含まれているかをEMSAで評価した。立体構造を形成させるためのフォールディング操作を実施し、sIL-6Rは結合溶液で所定の濃度に希釈した。それぞれを混合し、室温で30分間保温し、8%未変性ポリアクリルアミドゲルで解析した(図7)。その結果、最終ラウンドのDNAプールには、sIL-6Rの濃度が濃くなるについて結合した明確なシフトバンドが検出されたことより、スクリーニングで得られたDNAプールにはsIL-6Rに結合するDNA配列が濃縮していることが明らかとなった。
次世代シーケンサー(Ion PGMシステム)を用いて、スクリーニングで得られたDNAプールに含まれている配列を解析した。セレクション用Forward primer2とセレクション用Reverse Primer2間の挿入塩基長に変化がなく、さらに人工塩基dDscpが残存している配列群をクラスタリングした結果、存在割合が約22%と高い単一配列を同定した。
最も多く濃縮していた候補配列が標的タンパク質に結合するかどうかをEMSAによって解析した。まず候補配列に相当するオリゴマー(T-00247、配列下記参照)を化学合成法で合成し、OPC(カートリッジ)で精製を行った。精製した候補配列のオリゴを結合溶液中に0.2μMになるように調製し、フォールディング操作(95℃、5分間→(-0.1℃/秒)→25℃)を行うことで、三次構造を形成させた。その後sIL-6Rを結合溶液で0.6μMに希釈し、フォールディング済みDNA溶液と混合させ、室温で30分間保温させた。保温後の試料を8%未変性ポリアクリルアミドゲルで泳動し、DNA-タンパク質複合体のバンドを検出できるかどうかを分析した。DNAはSYBR Goldで染色させ、470nmのblue lightで検出させた。その結果、sIL-6R存在下で、新たなバンドが検出された(図8の左側の2レーン)ことから、本スクリーニングで同定した配列はsIL-6Rに結合するアプタマーであることを明らかとなった。
Claims (16)
- R1がフェニル基、4-ピリジル基、ナフチル基、イソプロピル基、シクロペンチル基である請求項1に記載のデオキシリボヌクレオシドまたはデオキシリボヌクレオチド。
- 5´-水酸基に三リン酸を有する、請求項1または2に記載のデオキシリボヌクレオチド。
- 5´-水酸基に保護基を有し、3´-水酸基にホスホロアミダイト基またはH-ホスホネート基を有する、請求項1または2に記載のデオキシリボヌクレオシド。
- 請求項1から4のいずれか1項に記載のデオキシリボヌクレオシドまたはデオキシリボヌクレオチドを含む、オリゴ核酸合成用試薬。
- 請求項1から4のいずれか1項に記載のデオキシリボヌクレオシドまたはデオキシリボヌクレオチドを含む、医薬品。
- 2-ブロモチオフェン誘導体と、2-アミノ-3-ニトロ-4-クロロピリジンまたは7-クロロ-3H-イミダゾ[4,5-b]ピリジン誘導体とのカップリング反応を行う工程を含む、請求項1または2に記載のデオキシリボヌクレオシドの合成法。
- 前記カップリング反応を、鈴木カップリング反応条件下で行う、請求項7に記載の合成法。
- 請求項1または2に記載の塩基を有するデオキシリボヌクレオシドが組み込まれたオリゴデオキシリボ核酸。
- 請求項9に記載のオリゴデオキシリボ核酸を部分構造として含む、オリゴ核酸またはその誘導体。
- 請求項9のオリゴデオキシリボ核酸、または、請求項10に記載のオリゴ核酸またはその誘導体に、独立した任意の分子種を結合させた修飾体。
- 請求項9に記載のオリゴデオキシリボ核酸、請求項10に記載のオリゴ核酸もしくはその誘導体、または請求項11に記載の修飾体を含有する、ヒトもしくは動物用医薬品、該医薬品の原料、健康食品の添加物、または診断試薬。
- 請求項9に記載のオリゴデオキシリボ核酸、請求項10に記載のオリゴ核酸もしくはその誘導体、または請求項11に記載の修飾体を含有する、医療用品。
- 医療用材料、医療用資材、医療機器、または医療用製品である、請求項13に記載の医療用品。
- 請求項9に記載のオリゴデオキシリボ核酸、請求項10に記載のオリゴ核酸もしくはその誘導体、または請求項11に記載の修飾体を含有する、アフィニティーカラムクロマトグラフィーに用いる担体。
- 請求項15に記載の担体を備えたカラム、物質分離用機器または医療機器。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022570066A JPWO2022131350A1 (ja) | 2020-12-18 | 2021-12-16 | |
KR1020237024552A KR20230123501A (ko) | 2020-12-18 | 2021-12-16 | Dna 앱타머의 스크리닝에 사용 가능한 신규 인공 염기를갖는 디옥시리보뉴클레오시드, 디옥시리보뉴클레오티드, 및 이를 함유하는 핵산 |
CN202180084570.1A CN116635038A (zh) | 2020-12-18 | 2021-12-16 | 具有可用于dna适体筛选的新型人工碱基的脱氧核糖核苷、脱氧核糖核苷酸、及核酸 |
EP21906710.5A EP4265726A1 (en) | 2020-12-18 | 2021-12-16 | Deoxyribonucleoside or deoxyribonucleotide having novel artificial base capable of being used for screening for dna aptamer, and nucleic acid containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020210488 | 2020-12-18 | ||
JP2020-210488 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022131350A1 true WO2022131350A1 (ja) | 2022-06-23 |
Family
ID=82059534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/046645 WO2022131350A1 (ja) | 2020-12-18 | 2021-12-16 | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4265726A1 (ja) |
JP (1) | JPWO2022131350A1 (ja) |
KR (1) | KR20230123501A (ja) |
CN (1) | CN116635038A (ja) |
WO (1) | WO2022131350A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199617A (ja) * | 2005-01-20 | 2006-08-03 | Institute Of Physical & Chemical Research | イミダゾピリジン誘導体 |
WO2007066737A1 (ja) * | 2005-12-09 | 2007-06-14 | Riken | 核酸の複製の方法及び新規人工塩基対 |
US20120219963A1 (en) * | 2009-10-30 | 2012-08-30 | Gerd Wagner | Derivatives of uridine phosphate and their uses in protein binding assays |
JP5424414B2 (ja) | 2008-03-31 | 2014-02-26 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
JP6307675B2 (ja) | 2011-11-18 | 2018-04-11 | タグシクス・バイオ株式会社 | 標的タンパク質に結合する核酸断片 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2763958B2 (ja) | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ,インコーポレイテッド | 核酸リガンド |
-
2021
- 2021-12-16 KR KR1020237024552A patent/KR20230123501A/ko unknown
- 2021-12-16 WO PCT/JP2021/046645 patent/WO2022131350A1/ja active Application Filing
- 2021-12-16 CN CN202180084570.1A patent/CN116635038A/zh active Pending
- 2021-12-16 EP EP21906710.5A patent/EP4265726A1/en active Pending
- 2021-12-16 JP JP2022570066A patent/JPWO2022131350A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199617A (ja) * | 2005-01-20 | 2006-08-03 | Institute Of Physical & Chemical Research | イミダゾピリジン誘導体 |
WO2007066737A1 (ja) * | 2005-12-09 | 2007-06-14 | Riken | 核酸の複製の方法及び新規人工塩基対 |
JP5424414B2 (ja) | 2008-03-31 | 2014-02-26 | 独立行政法人理化学研究所 | 高選択・高効率でpcr増幅が可能な新規dna |
US20120219963A1 (en) * | 2009-10-30 | 2012-08-30 | Gerd Wagner | Derivatives of uridine phosphate and their uses in protein binding assays |
JP6307675B2 (ja) | 2011-11-18 | 2018-04-11 | タグシクス・バイオ株式会社 | 標的タンパク質に結合する核酸断片 |
Non-Patent Citations (5)
Title |
---|
DILIP K TOSH ET AL., J. MED. CHEM., no. 55, 2012, pages 4847 - 4860 |
GUPTA S ET AL., J. BIOL. CHEM., 2014, pages 8706 - 19 |
LARRY GOLD ET AL., PLOS ONE, vol. 5, no. 11, 2010, pages e15004 |
MICHIKO KIMOTO ET AL., NATURE BIOTECHNOLOGY, no. 31, 2013, pages 453 - 457 |
NUCLEIC ACIDS RESEARCH, no. 37, 2009, pages e14 |
Also Published As
Publication number | Publication date |
---|---|
EP4265726A1 (en) | 2023-10-25 |
JPWO2022131350A1 (ja) | 2022-06-23 |
CN116635038A (zh) | 2023-08-22 |
KR20230123501A (ko) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5645840B2 (ja) | リン原子修飾核酸の合成方法 | |
JP5493117B2 (ja) | オリゴヌクレオチド誘導体及びその利用 | |
US7741472B2 (en) | Polynucleotide containing a phosphate mimetic | |
US20100009865A1 (en) | Oligonucleotide arrays | |
KR20160078989A (ko) | 시티딘-5-카르복스아미드 변형된 뉴클레오티드 조성물 및 그와 관련된 방법들 | |
JPH10304889A (ja) | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 | |
WO2011043385A1 (ja) | 特異な塩基対を形成する人工塩基対 | |
JPH06506910A (ja) | シロキサン橋によるヌクレオシドの結合方法 | |
KR20140091750A (ko) | 표적 단백질에 결합하는 핵산 단편 | |
Taherpour et al. | 2, 6-Bis (functionalized) purines as metal-ion-binding surrogate nucleobases that enhance hybridization with unmodified 2′-O-methyl oligoribonucleotides | |
JPH10509740A (ja) | カチオン性オリゴヌクレオチド、ならびに関連の合成および使用の方法 | |
JP2019521096A (ja) | 核酸シーケンシングにとって有用なタグ付きマルチヌクレオチド | |
Horiba et al. | Synthesis of scpBNA-mC,-A, and-G monomers and evaluation of the binding affinities of scpBNA-modified oligonucleotides toward complementary ssRNA and ssDNA | |
CN116655715A (zh) | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 | |
Kumar et al. | The Extension of a DNA Double Helix by an Additional Watson–Crick Base Pair on the Same Backbone | |
WO2022131350A1 (ja) | Dnaアプタマーのスクリーニングに使用可能な新規人工塩基を有するデオキシリボヌクレオシド、デオキシリボヌクレオチド、およびこれを含有する核酸 | |
US20240182908A1 (en) | Deoxyribonucleoside or deoxyribonucleotide having novel artificial base applicable to screening for dna aptamer, and nucleic acid containing the same | |
Dalager et al. | Double-headed nucleotides introducing thymine nucleobases in the major groove of nucleic acid duplexes | |
WO2011029835A2 (en) | Probes comprising fluorescent artificial nucleobases and use thereof for detection of single base alteration | |
JP5464401B2 (ja) | オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を用いたオリゴヌクレオチド構築物、オリゴヌクレオチド誘導体を合成するための化合物及びオリゴヌクレオチド誘導体の製造方法 | |
CN104262437A (zh) | 非天然碱基单体-杂环并吡啶硫酮脱氧核糖核苷三磷酸及其衍生物的合成方法 | |
Seio et al. | Short-RNA selective binding of oligonucleotides modified using adenosine and guanosine derivatives that possess cyclohexyl phosphates as substituents | |
JP5424236B2 (ja) | オリゴヌクレオチド誘導体、オリゴヌクレオチド誘導体を用いたオリゴヌクレオチド構築物、オリゴヌクレオチド誘導体を合成するための化合物及びオリゴヌクレオチド誘導体の製造方法 | |
JPWO2022131350A5 (ja) | ||
Park et al. | Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21906710 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084570.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022570066 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237024552 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021906710 Country of ref document: EP Effective date: 20230718 |